Unusual cause of acute abdominal pain: Eosinophilic colitis case report and review of the literature

S Bouchrit*, A Ait Errami, Z Samlani, S Oubaha and K Krati
Department of Gastroenterology, CHU Mohamed VI, Marrakech, Morocco

Abstract
Eosinophilic colitis is an exceptionally rare condition, the clinical symptoms is polymorphic and non-specific. The diagnosis is based on the grouping of endoscopic and essentially histological, clinical arguments. We describe the case of a male patient with eosinophilic colitis revealed by bloody mucous diarrhea and acute abdominal pain.

The diagnosis has been made after eliminating the parasitic, inflammatory and drug causes. This posed a diagnostic problem for us because of the non-specific symptoms associated with the lack of standardized histological criteria and the lack of clear, codified consensus regarding treatment.

Introduction
Eosinophilic colitis is a rare disease of the digestive tract characterized by abnormal infiltration of the colonic mucosa by eosinophilic polynuclear cells. Since 1979, only a few cases of eosinophilic colitis have been reported [1]. Its exact prevalence remains unknown, with a peak prevalence in newborns and young adults and without any gender preference [1].

The digestive symptomatology of eosinophilic colitis is highly variable and nonspecific; the clinical symptoms are dominated by diarrhea and abdominal pain. There is no histological consensus to make the diagnosis of eosinophilic colitis a polynucleareosinophils rate greater than 40 per high magnification field in at least two different colonic segments could be the criterion used for the diagnosis [2].

We present in this work the case of eosinophilic colitis in a 69-year-old man and we discuss in the light of data from the literature the diagnostic and therapeutic modalities of this rare and ambiguous entity.

Case report
We report the case of a 69-year-old man, operated 6 years ago for localized prostatic adenocarcinoma, without any other particular pathological history, in particular no history of atopic diseases, no known food or drug allergy and no recent trip. Admitted in a table of mucous-bloody diarrhea at a rate of 3-4 stools/day evolving for 5 days aggravated by the installation of acute abdominal pain evolving for less than 24 hours in a context of apyrexia and conservation of the general state. On clinical examination, the patient was hemodynamically and respiratory stable, temperature at 37.5°C, maximum diffuse abdominal tenderness in the left iliac fossa, on rectal examination the finger cot came back soiled with stool and blood.

An abdominal CT scan was performed urgently objectifying a regular and circumferential parietal thickening of the descending colon, extended to the sigmoid loop, measuring 15mm thick extended over 20cm and obstructing the lumen in places, enhanced after injection of contrast product with hyperemia and infiltration of neighboring mesenteric fat. The free prostatectomy compartment without nodular lesions.

The biological blood test showed a predominantly eosinophilic hyperleukocytosis and the serum immunoglobulin E level assay was normal at 40KU/l (N <150 KU/l). The results of the biological test represented in the following Table 1.
A left colonoscopy performed with progression to the left colonic angle showing a fragile erythematous mucosa bleeding on contact with an interval of healthy mucosa, located in the descending colon of a large digging ulceration, staged biopsies were performed (Figure 1).

Anatomopathological study objective a subacute and chronic exulcerative and inflammatory reshuffles with a richness in eosinophils (more than 100 eosinophils/mm²), architectural disorganization, without signs of specificity or malignancy (Figure 2).

The three coproparasitological examinations of stools returned negative.

In front of blood eosinophilia, the richness in eosinophils in the histological study of colonic biopsies, the negativity of the copro-parasitological examinations of the stool, and the absence of secondary causes of colonic eosinophilia, the diagnosis of eosinophilic colitis was retained and the management was to put the patient on corticosteroid therapy (prednisone) orally full dose at 1mg/kg/day for 1 month then the diagnosis of eosinophilic colitis was retained and the patient on corticosteroid therapy (prednisone) orally full dose at 1mg/kg/day for 1 month.

The evolution with the corticosteroid therapy and diet was favorable with disappearance of symptoms, especially diarrhea and abdominal pain from the first week of corticosteroid therapy. Biological check-up at the 2nd week of treatment showed a decrease in the level of blood eosinophils to 3350/UL.

A colonoscopy realized after 6 weeks of treatment revealed a colonic mucosa with a slightly erythematous appearance without ulcerations or process with histological study of colonic biopsies an eosinophil level of 20 Eosinophils/mm².

**Discussion**

The accumulation of eosinophils in the digestive tract is a common phenomenon of several gastrointestinal pathologies, including IgE and non-IgE mediated food allergy (AA), eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis, Gastroesophageal Reflux Disease (GERD), drug reactions, parasitic infections, malignant diseases and inflammatory diseases of the digestive tract [3,4].

Gastroenteritis and eosinophilic colitis represent an estimated incidence of 22 to 28 cases / 100,000 in the United States [5]. The exact pathogenesis of eosinophilic gastrointestinal disorders is not yet known. They probably result from a complex interaction between environment, genetics and immunological factors [6].

Several epidemiological studies suggest an allergic component, in particular food allergies, which elicits a Th2-type immune response leading to the production of cytokines, such as interleukins, IL-4, IL-5, IL-13 and eotaxins-3. This results in intestinal eosinophilia, which further causes local inflammation by releasing toxic cationic proteins [7]. It can probably be both an IgE and non-IgE mediated disease [8].

The diagnosis of eosinophilic colitis is a diagnosis of exclusion, it is based on the association of non-specific gastrointestinal symptoms, the demonstration of an eosinophilic infiltration on the biopsies, and the exclusion of the causes secondary effects of eosinophilic infiltration such as parasitosis, drugs, chronic inflammatory digestive disease, malignant causes, autoimmunity damage and hypereosinophilic syndrome [8,9]. There are no standardized histological criteria to make the diagnosis [1]. Imaging results are nonspecific and may show thickening of the colonic wall as well as ascites in some cases [10].

The treatment of eosinophilic enterocolitis remains a challenge in the absence of specific recommendations as there are no controlled trials to date on a specific treatment [11]. So far, the treatment of eosinophilic enterocolitis has been empirical and based on the severity of clinical manifestations, as well as the experience of clinicians. Patients with mild disease can be treated symptomatically, while more symptomatic patients and those with signs of malabsorption need more aggressive treatment [12].

A high proportion of cases of eosinophilic gastroenteritis are associated with food allergy. Therefore, diet therapy can improve symptoms [10]. It involves a “six-food elimination
diet”, avoiding milk, soy, eggs, wheat, peanuts, tree nuts and shellfish.

Corticosteroids are the optimal therapy for the induction of remission. Oral prednisone is the most common therapy, with an initial dose of 0.5-1mg/kg and decreased over a period of 6-8 weeks. Relapses can occur and require low maintenance doses (1 to 10mg / day) of prednisolone [13] or the substitution of prednisolone by budesonide which has a better safety profile [14,15].

Other therapies targeting immune modulation have been described in reports and small case series are likely to be helpful in treating recurrent or refractory symptoms. They include mast cell inhibitors such as cromolyn, ketotifen, leukotriene receptor antagonists, anti-IL-5 antibodies, omalizumab and anti-IgE monoclonal antibodies [12].

Conclusion

Our clinical case highlights a rare condition of the digestive tract which is often underdiagnosed. Eosinophilic colitis is rarely described and remains a diagnosis by exclusion, hence the need for further studies in order to better define the diagnostic criteria and the therapeutic attitude towards this rare and unknown entity.

References

1. Bates AWH (2012) Diagnosing eosinophilic colitis: histopathological pattern or nosological entity? Scientifica (Cairo) 2012: 682576. Link: http://bit.ly/3uYAOxJ
2. Gilles Macaigne (2018) Adult eosinophilic colitis. Hepato-Gastro & Digestive Oncology 25: 792-802.
3. Rothenberg ME (2004) Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 113: 11-28. Link: http://bit.ly/3uUpVwP
4. Furuta GT, Forbes D, Boey C, Dupont C, Putnam P, et al. (2008) Eosinophilic Gastrointestinal Diseases Working Group. Eosinophilic gastrointestinal diseases (EGIDs). J Pediatr Gastroenterol Nut 47: 234-238. Link: http://bit.ly/3kKWcBP
5. Spiegel JM, Book WM, Mays E, Song L, Shah SS, et al. (2011) Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nut 52: 300-305. Link: http://bit.ly/3ecAOcC
6. Lopes Azevedo R, Pinto J, Ribeiro H, Pereira F, Leitão C, et al. (2018) Eosinophilic Enterocolitis: An Excellently Rare Entity. GE Port J Gastroenterol 25: 184-188. Link: http://bit.ly/30corzF
7. Cherian ET, Zhang HC, Gutenberg KB, Everett JM. Guha S (2018) Looking Beyond the Obvious: Eosinophilic Enterocolitis. Am J Med 131: e227-e229. Link: http://bit.ly/3c7F3XJ
8. Alfadda AA, Storr MA, Shaffer EA (2011) Eosinophilic colitis: an update on pathophysiology and treatment. Br Med Bull 100: 59-72. Link: https://bit.ly/3riL5CF
9. Samiullah, Bhurgri H, Sohail U (2016) Eosinophilic disorders of the gastrointestinal tract. Prim Care 43: 495-504. Link: http://bit.ly/3c3CUUf
10. Zhang M, Li Y (2017) Eosinophilic gastroenteritis: a state-of-the-art review. J Gastroenterol Hepatol 32: 64-72. Link: http://bit.ly/3u20ABJ
11. Uppal V, Kreiger P, Kutch E (2016) Eosinophilic gastroenteritis and colitis: a comprehensive review. Clin Rev Allergy Immunol 50: 175-188. Link: http://bit.ly/3mu2kIS
12. Sunkara T, Rawla P, Yarlagadda KS, Gaduputi V (2019) Eosinophilic gastroenteritis: diagnosis and clinical perspectives. Clin Exp Gastroenterol 12: 239-253. Link: http://bit.ly/3c7h05c
13. Wong GW, Lim KH, Wan WK, Low SC, Kong SC (2015) Eosinophilic gastroenteritis: clinical profiles and treatment outcomes, a retrospective study of 18 adult patients in a Singapore Tertiary Hospital. Med J Malaysia 70: 232-237. Link: http://bit.ly/2M2Qxq4
14. Busoni VB, Lifschitz C, Christiansen S, GdD MT, Orsi M (2011) Eosinophilic gastroenteropathy: a pediatric series. Arch Argent Pediatr 109: 68-73. Link: http://bit.ly/38cfpHt
15. Lombardi C, Salmi A, Passalacqua G (2011) An adult case of eosinophilic pyloric stenosis maintained on remission with oral budesonide. Eur Ann Allergy Clin Immunol 4: 29-30. Link: http://bit.ly/3kM7yWl